Lecheng pilot zone gears up for win-win cooperation

On August 10, a strategic cooperation agreement was signed by four enterprises in the Lecheng pilot zone: Medi Center, Bee Tech (a wholly-owned health technology subsidiary of SCOR), Hainan Boao Lecheng International Medical Tourism Pilot Zone Central Pharmacy Co Ltd and Fosun Kite Biotechnology Co Ltd.

According to the agreement, the four enterprises will give full play to their resource advantages to collaborate in such fields as innovative medical devices and advanced therapies, health and wellness care, and health management.

They aim to expedite the adoption and execution of cutting-edge global therapies, enhance the availability of top-notch medical and health services, and address the medical and wellness requirements of both domestic and international patients.

The cooperation project stands as a noteworthy accomplishment in recent investment promotion within the Lecheng pilot zone, underscored by two pivotal aspects.

Firstly, it introduces stock policies from SCOR in Southeast Asia into the Lecheng pilot zone. This strategic move harnesses the medical resource and cost advantages inherent to the Lecheng pilot zone to attract more customers from Southeast Asia for medical tourism. Secondly, it facilitates the implementation of Fosun kite’s innovative CAR-T therapy within the Lecheng pilot zone. In tandem with insurance institutions, the endeavor seeks to enhance the affordability of this treatment, benefiting cancer patients both domestically and internationally.

Lyu Xiaolei, a member of the Party Committee and an executive deputy director of the Lecheng Pilot Zone Administration, emphasized that Lecheng is dedicated to integrating resources, including medical institutions, pharmaceutical enterprises, and insurance companies. This aims to foster collaboration throughout the entire industry chain, while creating a platform for industrial development and fostering an innovative environment.

Market participants can pool resources and engage in cooperative ventures with a primary focus on enhancing the accessibility and affordability of innovative pharmaceuticals. By continuously introducing diverse product portfolios and comprehensive service solutions for patients, the ultimate objective is to achieve cooperative success for all market entities.